Effect of neuroendocrine differentiation on therapeutic efficacy of abiraterone and docetaxel as first-line therapy in metastatic castration-resistant prostate cancer.
Effect of neuroendocrine differentiation on therapeutic efficacy of abiraterone and docetaxel as first-line therapy in metastatic castration-resistant prostate cancer.
复制标题
DOI：
10.1200/jco.2023.41.6_suppl.216
复制
发表时间：
2023
期刊：
影响因子：
--
通讯作者：
Yaowen
中科院分区：
文献类型：
--
作者：
Nanwei Xu;Jinge Zhao;Fengnian Zhao;Haoyang Liu;Wenlian Yin;Sha Zhu;Ling Nie;Guangxi Sun;Linmao Zheng;Zhenhua Liu;Diming Cai;Junru Chen;Jindong Dai;Yuchao Ni;Zhipeng Wang;Xingming Zhang;Jiayu Liang;Yuntian Chen;Xu Hu;Xiuyi Pan;Xiaoxue Yin;Xudong Zhu;Yaowen
216 Background: This study aims to explore the prognostic value of neuroendocrine differentiation (NED) in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving abiraterone or docetaxel therapy. Methods: We retrospectively analyzed data of 262 mCRPC patients treated with abiraterone or docetaxel as first-line therapy. NED status was evaluated using prostate biopsy samples at the time of mCRPC by immunohistochemical staining. Kaplan-Meier curves and Cox regression were used to assess the association between NED and treatment outcomes including PSA progression-free survival (PSA-PFS), radiographic progression-free survival (rPFS), and overall survival (OS). Results: In total, NED was confirmed in 100/262 (38.2%) mCRPC patients, with 76/100 (76.0%) and 24/100 (24.0%) men harboring NED
